FIDAS-3

FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC 50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A) . FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities In Vitro FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21 WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LS174T colorectal cancer (CRC) cells Concentration: 3 μM Incubation Time: 7 days Result: Significantly inhibited the proliferation of LS174T cells. In Vivo FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J athymic nude mice (6-8 week) injected with LS174 cellsDosage: 20 mg/kg Administration: Intraperitoneal injection; daily; for one months Result: Significantly inhibited the growth of xenograft tumors. Form:Solid IC50& Target:IC50: 4.9 μM (Methionine S-adenosyltransferase 2A (MAT2A))

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet